GT Biopharma Inc reports results for the quarter ended in September - Earnings Summary

GT Biopharma

01/11/2023 14:08

* GT Biopharma Inc  GTBP.OQ  reported a quarterly adjusted
loss
of 6 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -22 cents.  The lone analyst forecast for the
quarter was for a loss of 10 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * GT Biopharma Inc's reported EPS for the quarter was a loss
of 6
cents​.
    * The company reported a quarterly loss of $2.42 million.
    * GT Biopharma Inc shares had risen by 3.3% this quarter and
lost 71.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $5.00 

This summary was machine generated from LSEG data November 1 at
02:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.10          -0.06          Beat
 Jun. 30 2023      -0.10          -0.05          Beat
 Mar. 31 2023      -0.14          -0.01          Beat
 Dec. 31 2022      -0.17          -0.18          Missed